The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...
More than 8 million Americans live with psoriasis every day. Living with the chronic disease can be a long journey for many ...
Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.
A group of researchers have created four novel laboratory-developed tests that can distinguish between and subclassify atopic ...
In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...
A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback